DNA methylation changes in prostate cancer: current developments and future clinical implementation

References

• Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur. J. Cancer41(6), 858–887 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J. Natl Cancer Inst.94(13), 958–960 (2002).
   PubMedGoogle Scholar
• Alers JC, Krijtenburg PJ, Vis AN et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am. J. Pathol.158(2), 399–406 (2001).
   PubMedGoogle Scholar
• Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol.169(2), 517–523 (2003).
   PubMed Web of Science ®Google Scholar
• Barratt AL, Coates AS. Screening decreases prostate cancer death: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial. Med. J. Aust.181(4), 213–214 (2004).
   PubMedGoogle Scholar
• Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec Prospective Randomized Controlled Trial. Prostate38(2), 83–91 (1999).
   PubMedGoogle Scholar
• Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res.72, 141–196 (1998).
   PubMed Web of Science ®Google Scholar
• Bird A. The essentials of DNA methylation. Cell70(1), 5–8 (1992).
   PubMed Web of Science ®Google Scholar
• Merlo A, Herman JG, Mao L et al. 5´ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med.1(7), 686–692 (1995).
   PubMed Web of Science ®Google Scholar
• Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA95(12), 6870–6875 (1998).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol.23(27), 6569–6575 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br. J. Cancer100(2), 240–245 (2009).
   PubMed Web of Science ®Google Scholar
• Nelson WG, Yegnasubramanian S, Agoston AT et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci.12, 4254–4266 (2007).
   PubMed Web of Science ®Google Scholar
• Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol.177(3), 822–831 (2007).
   PubMed Web of Science ®Google Scholar
• Li LC. Epigenetics of prostate cancer. Front. Biosci.12, 3377–3397 (2007).
   PubMedGoogle Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet.8(4), 286–298 (2007).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Kim MS, Ostrow KL et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res.68(8), 2661–2670 (2008).
   PubMed Web of Science ®Google Scholar
• Ngan RK, Lau WH, Yip TT et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann. NY Acad. Sci.945, 73–79 (2001).
   PubMedGoogle Scholar
• Lo YM. Prognostic implication of pretreatment plasma/serum concentration of Epstein–Barr virus DNA in nasopharyngeal carcinoma. Biomed. Pharmacother.55(7), 362–365 (2001).
   PubMedGoogle Scholar
• Sidransky D, Von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science252(5006), 706–709 (1991).
   PubMed Web of Science ®Google Scholar
• Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat. Rev. Cancer7(7), 531–543 (2007).
   PubMedGoogle Scholar
• Hoque MO, Begum S, Topaloglu O et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res.64(15), 5511–5517 (2004).
   PubMed Web of Science ®Google Scholar
• Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res.10(7), 2284–2288 (2004).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst.98(14), 996–1004 (2006).
   PubMedGoogle Scholar
• Hoque MO, Feng Q, Toure P et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol.24(26), 4262–4269 (2006).
   PubMed Web of Science ®Google Scholar
• Henrique R, Costa VL, Cerveira N et al. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J. Mol. Med.84(11), 911–918 (2006).
   PubMed Web of Science ®Google Scholar
• Henrique R, Jeronimo C, Hoque MO et al. Frequent 14-13-3s promoter methylation in benign and malignant prostate lesions. DNA Cell Biol.24(4), 264–269 (2005).
   PubMedGoogle Scholar
• Henrique R, Jeronimo C, Hoque MO et al.MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol. Biomarkers Prev.14(5), 1274–1278 (2005).
   PubMedGoogle Scholar
• Henrique R, Jeronimo C, Teixeira MR et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol. Cancer Res.4(1), 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Henrique R, Ribeiro FR, Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res.13(20), 6122–6129 (2007).
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Henrique R, Hoque MO et al. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res.10(24), 8472–8478 (2004).
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology60(6), 1131–1135 (2002).
   PubMed Web of Science ®Google Scholar
• Nakayama M, Bennett CJ, Hicks JL et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol.163(3), 923–933 (2003).
   PubMed Web of Science ®Google Scholar
• Lombaerts M, van Wezel T, Philippo K et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer94(5), 661–671 (2006).
   PubMed Web of Science ®Google Scholar
• Li LC, Shiina H, Deguchi M et al. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem. Biophys. Res. Commun.321(2), 455–461 (2004).
   PubMed Web of Science ®Google Scholar
• Wang Q, Williamson M, Bott S et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene26(45), 6560–6565 (2007).
   PubMed Web of Science ®Google Scholar
• Kwabi-Addo B, Ren C, Ittmann M. DNA methylation and aberrant expression of sprouty1 in human prostate cancer. Epigenetics4(1) (2009).
   PubMedGoogle Scholar
• Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate66(6), 613–624 (2006).
   PubMed Web of Science ®Google Scholar
• Enokida H, Shiina H, Urakami S et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res.11(18), 6582–6588 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Shigematsu H, Shivapurkar N et al. Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett.242(2), 222–230 (2006).
   Google Scholar
• Bachmann N, Haeusler J, Luedeke M et al. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet. Cytogenet.182(2), 103–110 (2008).
   PubMedGoogle Scholar
• Cui J, Rohr LR, Swanson G et al. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate46(3), 249–256 (2001).
   PubMed Web of Science ®Google Scholar
• Padar A, Sathyanarayana UG, Suzuki M et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res.9(13), 4730–4734 (2003).
   PubMedGoogle Scholar
• Rosenbaum E, Hoque MO, Cohen Y et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res.11(23), 8321–8325 (2005).
   PubMed Web of Science ®Google Scholar
• Hanson JA, Gillespie JW, Grover A et al. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl Cancer Inst.98(4), 255–261 (2006).
   PubMed Web of Science ®Google Scholar
• Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate55(3), 199–205 (2003).
   PubMed Web of Science ®Google Scholar
• Woodson K, O’Reilly KJ, Ward DE et al.CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics1(4), 183–186 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Kim JW, Liu W et al. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate69(3), 327–335 (2009).
   PubMedGoogle Scholar
• Yamanaka M, Watanabe M, Yamada Y et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer106(3), 382–387 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson JB, Lee WH, Nguyen SH et al. Methylation of the 5´ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res.57(1), 35–37 (1997).
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Henrique R, Campos PF et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J. Clin. Pathol.56(1), 52–55 (2003).
   PubMedGoogle Scholar
• Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res.64(6), 1975–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Moriyama-Gonda N, Shiina H, Terashima M, Satoh K, Igawa M. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-α. BJU Int.101(4), 485–491 (2008).
   PubMedGoogle Scholar
• Sasaki M, Tanaka Y, Perinchery G et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J. Natl Cancer Inst.94(5), 384–390 (2002).
   PubMed Web of Science ®Google Scholar
• Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res.60(12), 3175–3182 (2000).
   PubMed Web of Science ®Google Scholar
• Zhu X, Leav I, Leung YK et al. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol.164(6), 2003–2012 (2004).
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res.8(2), 514–519 (2002).
   PubMed Web of Science ®Google Scholar
• Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA91(24), 11733–11737 (1994).
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst.93(22), 1747–1752 (2001).
   PubMed Web of Science ®Google Scholar
• Kim JW, Cheng Y, Liu W et al. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int. J. Cancer124(3), 734–738 (2009).
   PubMedGoogle Scholar
• Sathyanarayana UG, Padar A, M et al. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res.9(17), 6395–6400 (2003).
   PubMedGoogle Scholar
• Bastian PJ, Ellinger J, Wellmann A et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res.11(11), 4097–4106 (2005).
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Henrique R, Hoque MO et al. Quantitative RARβ2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res.10(12 Pt 1), 4010–4014 (2004).
   PubMedGoogle Scholar
• Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene21(44), 6835–6840 (2002).
   PubMed Web of Science ®Google Scholar
• Shah JN, Shao G, Hei TK, Zhao Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer8, 284 (2008).
   PubMed Web of Science ®Google Scholar
• Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer124(1), 88–94 (2009).
   PubMed Web of Science ®Google Scholar
• Guo L, Zhong D, Lau S et al. Sox7 Is an independent checkpoint for β-catenin function in prostate and colon epithelial cells. Mol. Cancer Res.6(9), 1421–1430 (2008).
   PubMedGoogle Scholar
• Aitchison AA, Veerakumarasivam A, Vias M et al. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate68(6), 661–674 (2008).
   PubMedGoogle Scholar
• Higuchi T, Nakamura M, Shimada K et al.HRK inactivation associated with promoter methylation and LOH in prostate cancer. Prostate68(1), 105–113 (2008).
   PubMedGoogle Scholar
• Yu YP, Yu G, Tseng G et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res.67(17), 8043–8050 (2007).
   PubMed Web of Science ®Google Scholar
• Pulukuri SM, Patibandla S, Patel J, Estes N, Rao JS. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene26(36), 5229–5237 (2007).
   PubMedGoogle Scholar
• Leiblich A, Cross SS, Catto JW et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene25(20), 2953–2960 (2006).
   PubMed Web of Science ®Google Scholar
• Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin. Cancer Res.12(5), 1412–1419 (2006).
   PubMedGoogle Scholar
• Vanaja DK, Ballman KV, Morlan BW et al.PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res.12(4), 1128–1136 (2006).
   PubMed Web of Science ®Google Scholar
• Yu G, Tseng GC, Yu YP et al.CSR1 suppresses tumor growth and metastasis of prostate cancer. Am. J. Pathol.168(2), 597–607 (2006).
   PubMedGoogle Scholar
• Kim H, Lapointe J, Kaygusuz G et al. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res.65(18), 8118–8124 (2005).
   PubMed Web of Science ®Google Scholar
• Ropke A, Buhtz P, Bohm M et al. Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer. Oncogene24(44), 6667–6675 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu L, Pfeifer GP. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor b gene. Oncogene23(12), 2241–2249 (2004).
   PubMed Web of Science ®Google Scholar
• Tokumaru Y, Sun DI, Nomoto S, Yamashita K, Sidransky D. Re: is TIG1 a new tumor suppressor in prostate cancer? J. Natl Cancer Inst.95(12), 919–920 (2003).
   PubMedGoogle Scholar
• Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol.3(12), 755–763 (2002).
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Liechty KC, Gentry FD et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res.66(6), 3338–3344 (2006).
   PubMed Web of Science ®Google Scholar
• Goessl C, Krause H, Muller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res.60(21), 5941–5945 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res.9(7), 2673–2677 (2003).
   PubMed Web of Science ®Google Scholar
• Yegnasubramanian S, Lin X, Haffner MC, DeMarzo AM, Nelson WG. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res.34(3), e19 (2006).
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA93(18), 9821–9826 (1996).
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology58(3), 335–338 (2001).
   PubMed Web of Science ®Google Scholar
• Cairns P, Esteller M, Herman JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res.7(9), 2727–2730 (2001).
   PubMed Web of Science ®Google Scholar
• Roupret M, Hupertan V, Yates DR et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res.13(6), 1720–1725 (2007).
   PubMed Web of Science ®Google Scholar
• Woodson K, O’Reilly KJ, Hanson JC et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J. Urol.179(2), 508–511; discussion: 511–502 (2008).
   PubMed Web of Science ®Google Scholar
• Vener T, Derecho C, Baden J et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin. Chem.54(5), 874–882 (2008).
   PubMed Web of Science ®Google Scholar
• Sunami E, Shinozaki M, Higano CS et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin. Chem.55(3), 559–67 (2009).
   PubMed Web of Science ®Google Scholar
• Reibenwein J, Pils D, Horak P et al. Promoter hypermethylation of GSTP1, AR, and 14-13-3s in serum of prostate cancer patients and its clinical relevance. Prostate67(4), 427–432 (2007).
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Palapattu GS, Yegnasubramanian S et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J. Urol.179(2), 529–534; discussion: 534–525 (2008).
   PubMedGoogle Scholar
• Ellinger J, Haan K, Heukamp LC et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate68(1), 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• Cottrell S, Jung K, Kristiansen G et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J. Urol.177(5), 1753–1758 (2007).
   PubMedGoogle Scholar
• Bastian PJ, Ellinger J, Heukamp LC et al. Prognostic value of CpG island hypermethylation at PTGS2, RAR-β, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur. Urol.51(3), 665–674; discussion: 674 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Shigematsu H, Shames DS et al. DNA methylation-associated inactivation of TGFβ-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br. J. Cancer93(9), 1029–1037 (2005).
   PubMedGoogle Scholar
• Bastian PJ, Palapattu GS, Lin X et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res.11(11), 4037–4043 (2005).
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Maekawa M. Polymerase chain reaction-based methods of DNA methylation analysis. Anal. Biochem.317(2), 259–265 (2003).
   PubMedGoogle Scholar
• Licchesi JD, Herman JG. Methylation-specific PCR. Methods Mol. Biol.507, 305–323 (2009).
   PubMedGoogle Scholar
• Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res.60(21), 5954–5958 (2000).
   PubMed Web of Science ®Google Scholar
• House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis24(2), 193–198 (2003).
   PubMed Web of Science ®Google Scholar
• van Engeland M, Weijenberg MP, Roemen GM et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res.63(12), 3133–3137 (2003).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J. Mol. Med.84(5), 365–377 (2006).
   PubMedGoogle Scholar
• Zeschnigk M, Bohringer S, Price EA et al. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res.32(16), e125 (2004).
   Web of Science ®Google Scholar
• Lo YM, Wong IH, Zhang J et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res.59(16), 3899–3903 (1999).
   PubMed Web of Science ®Google Scholar
• McCullagh P, Nelder JA. Generalized Linear Models (2nd Edition). Chapman and Hall, London, UK (1989).
   Google Scholar
• Kuppuswamy MN, Hoffmann JW, Kasper CK et al. Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (Factor IX) and cystic fibrosis genes. Proc. Natl Acad. Sci. USA88(4), 1143–1147 (1991).
   PubMed Web of Science ®Google Scholar
• Singer-Sam J, LeBon JM, Dai A, Riggs AD. A sensitive, quantitative assay for measurement of allele-specific transcripts differing by a single nucleotide. PCR Methods Appl.1(3), 160–163 (1992).
   PubMedGoogle Scholar
• Szabo PE, Mann JR. Allele-specific expression and total expression levels of imprinted genes during early mouse development: implications for imprinting mechanisms. Genes Dev.9(24), 3097–3108 (1995).
   PubMed Web of Science ®Google Scholar
• Greenwood AD, Burke DT. Single nucleotide primer extension: quantitative range, variability, and multiplex analysis. Genome Res.6(4), 336–348 (1996).
   PubMedGoogle Scholar
• Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res.25(12), 2529–2531 (1997).
   PubMed Web of Science ®Google Scholar
• Cottrell SE, Distler J, Goodman NS et al. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res.32(1), e10 (2004).
   PubMedGoogle Scholar
• Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res.61(4), 1659–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Sozzi G, Conte D, Mariani L et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res.61(12), 4675–4678 (2001).
   PubMed Web of Science ®Google Scholar
• Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem.242(1), 84–89 (1996).
   PubMed Web of Science ®Google Scholar
• Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science281(5375), 363–365(1998).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med.10(8), 789–799 (2004).
   PubMed Web of Science ®Google Scholar
• Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res.37(3), 646–650 (1977).
   PubMed Web of Science ®Google Scholar
• Chang HW, Lee SM, Goodman SN et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl Cancer Inst.94(22), 1697–1703 (2002).
   PubMed Web of Science ®Google Scholar
• Wang BG, Huang HY, Chen YC et al. Increased plasma DNA integrity in cancer patients. Cancer Res.63(14), 3966–3968 (2003).
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Yegnasubramanian S, Palapattu GS et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur. Urol.46(6), 698–708 (2004).
   PubMed Web of Science ®Google Scholar
• Nakayama M, Gonzalgo ML, Yegnasubramanian S et al.GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem.91(3), 540–552 (2004).
   PubMedGoogle Scholar
• Chuang CK, Chu DC, Tzou RD et al. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev.31(1), 59–63 (2007).
   PubMedGoogle Scholar
• Roupret M, Hupertan V, Catto JW et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer122(4), 952–956 (2008).
   PubMed Web of Science ®Google Scholar
• Rogers CG, Gonzalgo ML, Yan G et al. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J. Urol.176(5), 2280–2284 (2006).
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression. Annu. Rev. Pathol.1, 243–271 (2006).
   PubMed Web of Science ®Google Scholar
• Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. NY Acad. Sci.1137, 222–225 (2008).
   PubMed Web of Science ®Google Scholar
• Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J. Clin.54(1), 8–29 (2004).
   PubMed Web of Science ®Google Scholar
• Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int. J. Radiat. Oncol. Biol. Phys.57(4), 944–952 (2003).
   PubMedGoogle Scholar
• Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J. Clin. Oncol.20(16), 3376–3385 (2002).
   PubMed Web of Science ®Google Scholar
• Kuban DA, Thames HD, Levy LB et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int. J. Radiat. Oncol. Biol. Phys.57(4), 915–928 (2003).
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Shariat SF, Palapattu GS et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J. Urol.176(4 Pt 1), 1354–1361; discussion: 1361–1352 (2006).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol.17(5), 1499–1507 (1999).
   PubMed Web of Science ®Google Scholar